Approval Record: GARZULYS — EMERGE BIOSCIENCE PTE. LTD., ORIG (Not disclosed in the FDA record.)

Key facts

What was approved

FDA's record shows EMERGE BIOSCIENCE PTE. LTD. as the sponsor of GARZULYS, with the generic name recorded as unspecified and dosage form VIAL. A Biologics License Application (BLA) is the FDA pathway used to approve biologic products (such as vaccines, blood products, and cell/gene therapies), requiring evidence of safety, purity, and potency along with manufacturing-process validation specific to biologic manufacturing. This specific application is submission type ORIG (submission number 2) under application number BLA761497, with a submission status date of 20260915. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission. This record is drawn directly from FDA's own approvals database rather than from company press materials. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission.

Regulatory context

This application was reviewed under FDA's ORIG submission pathway. A Biologics License Application (BLA) is the FDA pathway used to approve biologic products (such as vaccines, blood products, and cell/gene therapies), requiring evidence of safety, purity, and potency along with manufacturing-process validation specific to biologic manufacturing. FDA approval of an application does not itself guarantee ongoing marketing; sponsors remain subject to post-approval manufacturing inspections and adverse-event reporting requirements. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission.

EMERGE BIOSCIENCE PTE. LTD.’s FDA history

Argus HQ has recorded 2 total FDA actions tied to EMERGE BIOSCIENCE PTE. LTD.: 0 warning letters, 0 recalls, 2 approval records, and 0 Form 483 inspection citations.

Frequently asked questions

What is the FDA application number for this submission?

FDA application number BLA761497, submission 2.

What review priority did FDA assign?

FDA designated this submission as: STANDARD.

What dosage form is GARZULYS?

GARZULYS is formulated as: VIAL.

What did FDA approve?

FDA's record shows bla approval for GARZULYS (unspecified), dosage form VIAL, sponsored by EMERGE BIOSCIENCE PTE. LTD., under application number BLA761497. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission.

Related enforcement actions

• Approval (recent): ZYDUS LIFESCIENCES — ANDA approval: TRETINOIN (unspecified) →
• Approval (recent): CURIUM — NDA approval: BEXLUTRY (unspecified) →
• Approval (recent): STRIDES PHARMA — ANDA approval: MILNACIPRAN HYDROCHLORIDE (unspecified) →
• Approval (recent): MACLEODS PHARMS — ANDA approval: MILNACIPRAN HYDROCHLORIDE (unspecified) →
• Approval (recent): ZYDUS LIFESCIENCES — ANDA approval: LETROZOLE (unspecified) →
• Approval (recent): DIFGEN PHARMS — ANDA approval: EPINEPHRINE (unspecified) →
• Approval (recent): AJANTA PHARMA LTD — ANDA approval: HALOPERIDOL (unspecified) →
• Approval (recent): AUROLIFE PHARMA LLC — ANDA approval: BECLOMETHASONE DIPROPIONATE (unspecified) →